CoronaryAtlas logo
CoronaryAtlas
Cardiac troponin I
Pathway / Myocardial injury (shared endpoint)

Cardiac troponin I

TNNI3protein

Cardiac troponin I is released from damaged cardiomyocytes following myocardial ischemia and necrosis and is the gold-standard biomarker for acute MI diagnosis, prognosis, and risk stratification.

Pathway placement
Cascade stepMyocardial injury (shared endpoint)
Confidencehigh
RationaleCardiac contractile protein released upon myocardial necrosis; primary biomarker for AMI diagnosis and risk stratification.
Druggability
DruggableYes
Known drugs / candidates1
Small-molecule tractableYes
Antibody tractableNo
EnsemblENSG00000129991

Type I vs non-Type I discrimination

ScoresShared / rises in both
R — rupture / Type-I
100
C — non-Type-I
62
A — assay feasibility
96
E — evidence strength
78
T1DI (composite)
61
Specificity differential (R−C)+62.1
Direct evidence: higher in Type I (D=+2)
hs-cTnI: T2MI 23 (10-83) ng/L vs T1MI 115 (28-576) ng/L; P<.001 (PMID 33881449)
Non-Type-I axis panel
Does this marker also move in each non-Type-I setting? mag 0–3; higher means less Type-I-specific. n/a = no evidence retrieved, which is not the same as no change.
2sepsis / systemic inflammationmag 2
2anemia / acute blood lossn/a
2hypovolemia / dehydrationmag 1
2tachyarrhythmian/a
2hypoxemia / respiratory failuremag 2
2hypertensive emergencymag 2
2high-demand / peri-operative stressn/a
3sudden cardiac deathmag 2
4aPCI-related periproceduralmag 2
4bstent thrombosisn/a
4cin-stent restenosisn/a
5CABG-relatedmag 2
Coverage: 7/12 axes with evidence
Tier: deep-scored (abstract-extracted) · 22 supporting references. See the discrimination table for all markers.

Assay & specimen

Validated clinical assay
Specimen
Serum or plasma
Collection tube
Serum separator (gold/red-top, SST) · Lithium heparin (green-top)
Method / principle
High-sensitivity chemiluminescent/ECL sandwich immunoassay
Reagent / substrate
Paired anti-cTnI monoclonal antibodies (capture+detection), acridinium/ruthenium label
Platform
Automated core-lab analyzer (Abbott Architect/Alinity, Siemens Atellica, Roche cobas); Abbott i-STAT POC
Turnaround · availability
STAT (~15–60 min) · FDA-cleared, universal

Human genetic evidence

0.269
Open Targets association (acute_MI)

Literature evidence(46)

Clinical trials(7)